Summary
Angiogenesis, defined as formation of new blood vessels, is a physiological process
necessary for embryonic development and wound repair. Angiogenesis is also an important
component of various pathologic events such as tissue ischemia, cancer, diabetic retinopathy,
and chronic inflammatory states including atherosclerosis. Among the key events leading to
angiogenesis is generation of reactive oxygen species (ROS) such as superoxide anions and
hydrogen peroxide which play a key role in physiological and pathophysiological states. LOX-1,
a lectin-like ox-LDL receptor, is responsible for binding and uptake of ox-LDL in endothelial
cells. It has been well documented that the activation of LOX-1 itself can stimulate the
formation of ROS and initiate a cascade of redox-sensitive signaling events. We postulate that
oxidized LDL (ox-LDL) at low concentrations activates LOX-1 in endothelial cells, induces low
levels of ROS release and initiates the angiogenic response.
Our specific aims in this proposal are:
Aim # 1: To study the effect of oxidized LDL (ox-LDL) on angiogenesis- These studies will
be done in human coronary artery endothelial cells, in an aortic ring model of angiogenesis, as
well as in wild-type and LOX-1 knock out (KO) mice.
Aim # 2: To define the mechanisms of ox-LDL-induced angiogenic response- These
studies will involve a number of specific inhibitors, LOX-1 antibody, siRNA against LOX-1, and
upregulation of LOX-1, and will involve state-of-art molecular biology approaches. Further, to
define the mechanism of the effects of ox-LDL, microarray technology will be utilized to identify
genes that are up-regulated and down-regulated during angiogenesis.
The strengths of the proposal are: 1. The PI has strong background on angiogenesis and
LOX-1 research. 2. The PI has LOX-1 KO mice in his possession. 3. Availability of well trained
molecular biologist well-versed in most aspects of the research. 4. One of the PI's team
members has extensive experience in microarray technology.
Significance: Understanding of the basis of formation of neovasculature may provide novel
information on the basis of atherogenesis, especially in the development of unstable lesions.
Information gained from this study may also have relevance in the development of cancers
which are dependent of neovasculature for their growth.
Public Health Relevance Statement
Narrative
Hardening of the arteries (also known as atherosclerosis) is the cause of heart attacks. As the area
covered with atherosclerosis grows, there is formation of small new blood vessels; a process called
"angiogenesis". Angiogenesis is caused in part by oxygen-derived molecules called reactive oxygen
species (ROS). Our work has shown that ROS stimulate a receptor for oxidized cholesterol called LOX-
1. The proposed experiments are designed to test the concept that oxidized cholesterol at low
concentration activates LOX-1, induces low levels of ROS release and initiates angiogenesis. In
contrast, high concentration of ROS causes much LOX-1 expression and cell injury. To confirm the role
of LOX-1 in angiogenesis, we will use specialized mice that lack the LOX-1. In the second set of
experiments, we will study the underlying mechanisms of angiogenesis by examining changes in genes.
Information from this study may be important in understanding the development of atherosclerosis and
certain cancers that are dependent of angiogenesis.
No Sub Projects information available for 5I01BX000282-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5I01BX000282-03
Patents
No Patents information available for 5I01BX000282-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5I01BX000282-03
Clinical Studies
No Clinical Studies information available for 5I01BX000282-03
News and More
Related News Releases
No news release information available for 5I01BX000282-03
History
No Historical information available for 5I01BX000282-03
Similar Projects
No Similar Projects information available for 5I01BX000282-03